This HTML5 document contains 109 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q57579457
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована в жовтні 2014 article scientifique publié en 2014 scientific article published on 28 September 2014 artículu científicu espublizáu en setiembre de 2014 wetenschappelijk artikel im September 2014 veröffentlicher wissenschaftlicher Artikel
p:P577
wds:Q57579457-FCE9D4BF-6D06-4B86-952A-5B9097C8A9A1
wdt:P577
2014-09-28T00:00:00Z
p:P2860
wds:Q57579457-08D4529B-A300-442C-BEC5-7FA977C3E35B wds:Q57579457-8F8DD0E9-EFF1-4ED6-A06F-9471A021FE47 wds:Q57579457-91C7F5EC-43B7-45DD-858D-E6899EF4C2E1 wds:Q57579457-63AF6F8F-4706-4F8C-987F-1F73B2C18672 wds:Q57579457-7F31E47B-5251-4E2D-A66C-ECB4A98F3263 wds:Q57579457-4AF0C946-0C32-4B38-8A36-0FF1448C8AF7 wds:Q57579457-4B37801E-ED2D-4DC9-8593-81503E67795D wds:Q57579457-30C13E92-5A37-4B03-8E27-DD695E506390 wds:Q57579457-30EFA6F1-FFBC-481C-8334-73ED9712A95F wds:Q57579457-386E9EDB-D292-4B97-A632-803BB3BF32B4 wds:Q57579457-DCB6DFFA-6ABF-4F70-9625-692BB0C59DD2 wds:Q57579457-DF2B10F6-EE5A-45C7-8662-8FE68343CF77 wds:Q57579457-D58F6944-7CCB-4ADD-978F-F5A2BED5FF85 wds:Q57579457-D64E100E-83B2-4633-BBA1-891BA350EE5C wds:Q57579457-B2639C9E-6895-4803-B463-086DEA7CF0F2 wds:Q57579457-C6B3E04D-7AAF-425B-9E9C-DBAAF649541B wds:Q57579457-A560C768-A47A-4E51-A816-BD07070262F7 wds:Q57579457-FC6847FA-EEBB-4A97-9E57-F051B09964B8 wds:Q57579457-E2593AB4-CFCC-47AD-AEDF-6EA29F090070
wdt:P2860
wd:Q85077949 wd:Q54523915 wd:Q29614302 wd:Q34638749 wd:Q87880547 wd:Q27851468 wd:Q82294729 wd:Q37909171 wd:Q34022546 wd:Q84735057 wd:Q39691997 wd:Q51762694 wd:Q44963911 wd:Q37259271 wd:Q43790301 wd:Q34645599 wd:Q39173162 wd:Q37231532 wd:Q71721709
p:P2093
wds:Q57579457-FCF85244-65DD-4C5D-9E2B-6E4E33134428 wds:Q57579457-F2026F70-0FD7-46A5-B0D1-3FF3A580A7B8 wds:Q57579457-C9E53490-E96B-4495-891B-99DB187E7670 wds:Q57579457-CEFBD101-9BFD-4DF0-A070-64021FDB4DD5 wds:Q57579457-DDDCD79D-A6B7-4606-8365-A7563F2F6450 wds:Q57579457-AD93E93C-C3A0-4AFA-94A8-632005A23251 wds:Q57579457-8A66D401-C71A-40AE-8C1F-237F737D8F66 wds:Q57579457-7CD6AB20-6CF2-4E28-B6B7-A124D9A70146 wds:Q57579457-A1CE7F17-013B-4ED0-936B-8C2B62B0959E wds:Q57579457-46B5DE06-5F4E-4D04-9907-4298A5D6D90A wds:Q57579457-2180CE1F-1B19-4507-9FFC-A62C8466A177
wdt:P2093
Cristian Villanueva Gunter von Minckwitz Gilles Romieu Corinne Veyret Stefanie Srock Norbert Marschner Ulrich Freudensprung Sabine de Ducla Eduard Vrdoljak István Lang Christoph Zielinski
rdfs:label
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando
skos:prefLabel
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando
schema:name
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando
p:P50
wds:Q57579457-1BBD5186-C43A-44AA-9BAC-066B67180B04 wds:Q57579457-1ECED9E3-A4E5-4F0E-91C9-88663BFAFFD3 wds:Q57579457-B04771B6-8BAF-4F77-A88F-E6C059121C8E wds:Q57579457-55505C0A-3146-46E2-9619-D160F544FB83 wds:Q57579457-950371A2-E7CF-4A29-B450-311ED24A4C6B
wdt:P50
wd:Q43114235 wd:Q39600020 wd:Q57081048 wd:Q40405518 wd:Q57085354
p:P1476
wds:Q57579457-5B252401-2D7A-40DC-96C4-B341D6C3B50E
wdt:P1476
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
p:P304
wds:Q57579457-074C976D-60FB-46D2-8867-DACEB20A1BC4
wdt:P304
1269-1278
p:P31
wds:Q57579457-E49F6FC0-0311-4BF3-8BF4-1D3D94747529
wdt:P31
wd:Q13442814
p:P921
wds:Q57579457-E6BE43AA-7AB8-46B1-AA36-4C482EB2599F wds:Q57579457-1D189841-E1F8-4DC3-93DF-35638DE41F36 wds:Q57579457-E534DB13-F253-4BB0-B5CD-EF8200B37420
wdt:P921
wd:Q974135 wd:Q12859063 wd:Q413299
p:P698
wds:Q57579457-E070179B-0991-4389-BC76-A93A51CD402F
wdtn:P698
n12:25273342
wdt:P698
25273342
p:P1433
wds:Q57579457-C9718178-A7EE-43FD-AEC5-DDE941646242
wdt:P1433
wd:Q13747613
p:P433
wds:Q57579457-A3291B8E-17B1-4208-A162-0248AE09A109
p:P478
wds:Q57579457-AC3850BB-820C-42E9-B51B-5CE80DC0C993
wdt:P433
11
wdt:P478
15
p:P356
wds:Q57579457-1DF1964B-FA73-4C83-9084-F742C94A0DAF
wdtn:P356
n11:S1470-2045(14)70439-5
wdt:P356
10.1016/S1470-2045(14)70439-5